AR038712A1 - Uso de epotilonas en el tratamiento de enfermedades cerebrales asociados con procesos proliferativos - Google Patents
Uso de epotilonas en el tratamiento de enfermedades cerebrales asociados con procesos proliferativosInfo
- Publication number
- AR038712A1 AR038712A1 ARP030100696A ARP030100696A AR038712A1 AR 038712 A1 AR038712 A1 AR 038712A1 AR P030100696 A ARP030100696 A AR P030100696A AR P030100696 A ARP030100696 A AR P030100696A AR 038712 A1 AR038712 A1 AR 038712A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- group
- aralkyl
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
) Uso de una epotilona que presenta un coeficiente de distribución promedio entre plasma y cerebro que comprende entre 0,3 y 1,5 en el ensayo de inyección de bolo intravenoso en ratón, en la preparación de un medicamento para el tratamiento de una enfermedad cerebral asociada con procesos proliferativos. Reivindicación 4: El uso de un compuesto, caracterizado porque dicho compuesto responde a la fórmula general (1) donde: R1a, R1b son, independientemente entre sí, hidrógeno, alquilo C1-10, arilo aralquilo; o forman juntos un grupo -(CH2)m-, donde m comprende entre 2 y 5; R2a, R2b son, independientemente entre sí, hidrógeno, alquilo C1-10, arilo, aralquilo; o forman juntos un grupo -(CH2)n, donde n comprende entre 2 y 5; o alquenilo C2-10; R3 es hidrógeno, alquilo C1-0, arilo, aralquilo; R4a, R4b son, independientemente entre sí, hidrógeno, alquilo C1-10, arilo, aralquilo; o forman juntos un grupo -(CH2)p, donde p comprende entre 2 y 5; R5 es hidrógeno, alquilo C1-10, arilo, aralquilo, CO2H, CO2 alquilo, CH2OH, CH2O alquilo, CH2O acilo, CN, CH2NH2, CH2N(alquilo, acilo)1,2 o CH2Hal; R6, R7 son, cada uno, hidrógeno; o forman juntos un enlace adicional o forman juntos una función epoxi; G es O ó CH2; D-E es un grupo H2C-CH2, HC=CH, C?C, CH(OH)-CH(OH); CH(OH)-CH2, CH2-CH(OH), CH2-O, O-CH2; o un resto de fórmula (2); W es un grupo C(=X)R8 o es un radical aromático o heteroaromático bi- o tricíclico; X es O ó dos grupos OR20 o un grupo alquilen(C2-10)-dioxi (que puede ser de cadena lineal o ramificada) o H/OR9 o un grupo CR10R11; R8 es hidrógeno, alquilo C1-10, arilo, aralquilo, halógeno, CN; R9 es hidrógeno o un grupo protector PGx; R10, R11 son, independientemente entre sí, hidrógeno, alquilo C1-20, arilo, aralquilo; o junto con el carbono del metileno forman un anillo carbocíclico de 5 a 7 miembros; Z es O ó H/OR12; R12 es hidrógeno o un grupo protector PGz; A-Y es un grupo O-C(=O), O-CH2, CH2-C(=O), NR21-C(=O), o NR21-SO2; R20 es un grupo alquilo C1-20; R21 es hidrógeno o alquilo C1-10; PGx, PGz es alquilo C1-20, cicloalquilo C4-7, que puede contener un átomo de oxígeno en el anillo, arilo, aralquilo, acilo C1-20, aroílo, alquilsulfonilo C1-20, arilsulfonilo, tri(alquil C1-20)sililo, di(alquil C1-20)arilsililo, (alquil C1-20)diarilsililo o tri(aralquil)sililo; como un estereoisómero único o una mezcla de distintos estereoisómeros y/o como una sal aceptable para uso farmacéutico del mismo, para la preparación de un medicamento destinado al tratamiento de una enfermedad cerebral asociada con procesos proliferativos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36106202P | 2002-03-01 | 2002-03-01 | |
| EP02004745A EP1340498A1 (en) | 2002-03-01 | 2002-03-01 | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038712A1 true AR038712A1 (es) | 2005-01-26 |
Family
ID=27675676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100696A AR038712A1 (es) | 2002-03-01 | 2003-03-03 | Uso de epotilonas en el tratamiento de enfermedades cerebrales asociados con procesos proliferativos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040019088A1 (es) |
| EP (2) | EP1340498A1 (es) |
| JP (1) | JP2005525360A (es) |
| KR (1) | KR20040095244A (es) |
| CN (1) | CN100473381C (es) |
| AR (1) | AR038712A1 (es) |
| AU (1) | AU2003215618B2 (es) |
| BR (1) | BR0308154A (es) |
| CA (1) | CA2477403A1 (es) |
| CR (1) | CR7444A (es) |
| EC (1) | ECSP045340A (es) |
| HK (1) | HK1079998A1 (es) |
| HR (1) | HRP20040892A2 (es) |
| IL (1) | IL163752A0 (es) |
| MX (1) | MXPA04008450A (es) |
| NO (1) | NO20044175L (es) |
| NZ (1) | NZ546617A (es) |
| PL (1) | PL370768A1 (es) |
| RU (1) | RU2351330C2 (es) |
| UA (1) | UA83798C2 (es) |
| WO (1) | WO2003074053A1 (es) |
| YU (1) | YU76404A (es) |
| ZA (1) | ZA200407905B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
| DE59814067D1 (de) | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| KR20010094763A (ko) * | 1999-02-11 | 2001-11-01 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | 에포틸론 유도체, 그 제조방법 및 제약적 용도 |
| US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| ES2281692T3 (es) | 2002-08-23 | 2007-10-01 | Sloan-Kettering Institute For Cancer Research | Sintesis de epotilones, sus intermediarios, sus analogos y sus usos. |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| DE10331004A1 (de) * | 2003-07-03 | 2005-02-24 | Schering Ag | Verfahren für die Herstellung von C1-C15-Fragmenten von Epothilonen und deren Derivaten |
| EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| EP1700596A1 (en) * | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
| DE102007016046A1 (de) | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
| CA2722371C (en) | 2008-04-24 | 2016-06-21 | Bristol-Myers Squibb Company | Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
| EP2793949B1 (en) | 2011-12-23 | 2018-08-22 | Innate Pharma | Enzymatic conjugation of antibodies |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN105517577A (zh) | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996041807A1 (en) * | 1995-06-09 | 1996-12-27 | Novartis Ag | Rapamycin derivatives |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| AU737621B2 (en) * | 1997-02-18 | 2001-08-23 | Canji, Inc. | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| DE59814067D1 (de) * | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| HUP0100582A3 (en) * | 1997-12-04 | 2003-03-28 | Bristol Myers Squibb Co | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| WO1999067253A2 (en) * | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
| PL349863A1 (en) * | 1999-02-18 | 2002-09-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
| PE20010116A1 (es) * | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
| CA2385528C (en) * | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| GB0013643D0 (en) * | 2000-05-31 | 2000-07-26 | Unilever Plc | Targeted moieties for use in bleach catalysts |
| JP2004532888A (ja) * | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
-
2002
- 2002-03-01 EP EP02004745A patent/EP1340498A1/en not_active Withdrawn
-
2003
- 2003-02-28 PL PL03370768A patent/PL370768A1/xx not_active Application Discontinuation
- 2003-02-28 BR BR0308154-0A patent/BR0308154A/pt not_active Withdrawn
- 2003-02-28 WO PCT/EP2003/002085 patent/WO2003074053A1/en active Application Filing
- 2003-02-28 JP JP2003572570A patent/JP2005525360A/ja active Pending
- 2003-02-28 IL IL16375203A patent/IL163752A0/xx unknown
- 2003-02-28 RU RU2004129325/15A patent/RU2351330C2/ru active
- 2003-02-28 YU YU76404A patent/YU76404A/sh unknown
- 2003-02-28 UA UA20040907817A patent/UA83798C2/ru unknown
- 2003-02-28 US US10/375,043 patent/US20040019088A1/en not_active Abandoned
- 2003-02-28 KR KR10-2004-7013549A patent/KR20040095244A/ko not_active Application Discontinuation
- 2003-02-28 NZ NZ546617A patent/NZ546617A/en unknown
- 2003-02-28 MX MXPA04008450A patent/MXPA04008450A/es not_active Application Discontinuation
- 2003-02-28 CN CNB038097613A patent/CN100473381C/zh not_active Expired - Fee Related
- 2003-02-28 AU AU2003215618A patent/AU2003215618B2/en not_active Expired - Fee Related
- 2003-02-28 EP EP03743360A patent/EP1480643A1/en not_active Withdrawn
- 2003-02-28 CA CA002477403A patent/CA2477403A1/en not_active Abandoned
- 2003-03-03 AR ARP030100696A patent/AR038712A1/es unknown
-
2004
- 2004-09-01 CR CR7444A patent/CR7444A/es not_active Application Discontinuation
- 2004-09-28 HR HRP20040892 patent/HRP20040892A2/hr not_active Application Discontinuation
- 2004-09-30 ZA ZA200407905A patent/ZA200407905B/en unknown
- 2004-09-30 NO NO20044175A patent/NO20044175L/no not_active Application Discontinuation
- 2004-09-30 EC EC2004005340A patent/ECSP045340A/es unknown
-
2006
- 2006-01-04 HK HK06100157.3A patent/HK1079998A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003215618A1 (en) | 2003-09-16 |
| CA2477403A1 (en) | 2003-09-12 |
| CR7444A (es) | 2005-10-05 |
| ECSP045340A (es) | 2004-11-26 |
| RU2004129325A (ru) | 2005-07-10 |
| HRP20040892A2 (en) | 2004-12-31 |
| UA83798C2 (ru) | 2008-08-26 |
| EP1480643A1 (en) | 2004-12-01 |
| IL163752A0 (en) | 2005-12-18 |
| NZ546617A (en) | 2007-12-21 |
| RU2351330C2 (ru) | 2009-04-10 |
| JP2005525360A (ja) | 2005-08-25 |
| ZA200407905B (en) | 2006-04-26 |
| YU76404A (sh) | 2006-08-17 |
| AU2003215618B2 (en) | 2009-06-04 |
| KR20040095244A (ko) | 2004-11-12 |
| PL370768A1 (en) | 2005-05-30 |
| CN100473381C (zh) | 2009-04-01 |
| CN1649587A (zh) | 2005-08-03 |
| NO20044175L (no) | 2004-12-01 |
| HK1079998A1 (zh) | 2006-04-21 |
| WO2003074053A1 (en) | 2003-09-12 |
| MXPA04008450A (es) | 2005-07-13 |
| BR0308154A (pt) | 2005-01-04 |
| US20040019088A1 (en) | 2004-01-29 |
| EP1340498A1 (en) | 2003-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038712A1 (es) | Uso de epotilonas en el tratamiento de enfermedades cerebrales asociados con procesos proliferativos | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| AR074822A1 (es) | Compuestos heterociclicos de pirazina utiles como inhibidores de proteinquinasas atr, composiciones farmaceuticas que los comprenden y uso de los mismos en el tratamiento del cancer | |
| ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
| ES2702128T3 (es) | Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación | |
| AR038202A1 (es) | Compuestos de indazol utiles como inhibidores de la proteina quinasa | |
| ATE387199T1 (de) | Neue substanzen und verbindungen als protease- inhibitoren | |
| UY29938A1 (es) | Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor | |
| CO5700741A2 (es) | Nuevos conjugados de efectores, procedimientos para su prepa racion y su uso farmaceutico | |
| PE20140411A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| CY1112178T1 (el) | Παραγωγα πιπεραζινης και χρηση αυτων ως θεραπευτικων παραγοντων | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| AR039222A1 (es) | Derivados de quinolina e isoquinolina, un metodo para su preparacion y su uso como inhibidores de la inflamacion | |
| AR068014A1 (es) | Derivados de pirimidin-2-il-amina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la cinasa. | |
| ECSP024364A (es) | Antagonistas receptores de adenosina a2a | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| AR042583A1 (es) | Macrolidos | |
| PE20080704A1 (es) | Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| ECSP066504A (es) | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina | |
| AR067156A1 (es) | DERIVADOS DE TETRAHIDRO-2H-PIRIDO(4,3-B)INDOL-2-ILO, UN PROCESO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA QUE LOS COMPRENDE Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA INHIBICION DE CATEPSINA K | |
| CO6241100A2 (es) | Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c | |
| GT200500253A (es) | Ligandos de difenil eter terapeuticos | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| AR041024A1 (es) | Derivados de benzimidazol como inhibidores del factor de coagulacion xa | |
| AR058055A1 (es) | Analogos de feniletilamina y su uso para el tratamiento del glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |